{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/itch-widespread/prescribing-information/hydroxyzine/","result":{"pageContext":{"chapter":{"id":"d3b77011-f1f7-5074-ac46-2c0f5e15406a","slug":"hydroxyzine","fullItemName":"Hydroxyzine","depth":2,"htmlHeader":"<!-- begin field 25575c22-d1ff-4038-b98b-5220ac480d09 --><h2>Hydroxyzine</h2><!-- end field 25575c22-d1ff-4038-b98b-5220ac480d09 -->","summary":"","htmlStringContent":"<!-- begin item eab534ea-f455-42e7-b9b9-061ad179da48 --><!-- end item eab534ea-f455-42e7-b9b9-061ad179da48 -->","topic":{"id":"98db983b-94d0-57fc-8f85-3c35dffdbc84","topicId":"3ff60e1b-3717-41cc-be12-1871b4284ba6","topicName":"Itch - widespread","slug":"itch-widespread","lastRevised":"Last revised in December 2016","chapters":[{"id":"c31a1ea7-3548-5767-9a55-10f56f4ea14a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"316853c8-d1ca-5613-8c4d-c33ea7c0fd8b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"64abf965-05aa-566d-999c-e216708a87b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d34f3906-2823-5407-8f4d-32157480544d","slug":"changes","fullItemName":"Changes"},{"id":"8981751b-abe1-515d-b935-74b8a9b645f8","slug":"update","fullItemName":"Update"}]},{"id":"e1e55a0f-0001-592a-92fd-aacfa519336f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f8e85ce4-cb59-5950-9bb6-f4cc07f650a5","slug":"goals","fullItemName":"Goals"},{"id":"49927afa-5b0d-5fc5-9977-b9fbb4cb4db9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0cdcfdc7-2628-54da-8125-7d0470463e91","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9249d5b2-8df4-5432-adc8-2c07129d2033","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"60200ae0-6fe3-5aac-ba12-bfadcd7364eb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f57416b9-dc21-5b4f-b045-1a09f5148e92","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b96f535e-5376-53fa-b81c-21c88d0b344f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5e603eed-2553-5ec5-8250-3b6ff59aa984","slug":"definition","fullItemName":"Definition"},{"id":"5d85e75d-599f-583b-843d-861aeef9a901","slug":"causes","fullItemName":"Causes"},{"id":"ac8f2843-31dd-59dc-a6ea-cb91a03a2ff5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a022a03-81bf-5f1b-a367-0ecb842aa8b3","slug":"complications","fullItemName":"Complications"}]},{"id":"5520e3e5-dfa1-5437-aeef-2256ca61fbb4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1cf86197-a1ad-58fc-b46d-d2814ed58a17","slug":"history-examination","fullItemName":"History and examination"},{"id":"3b7bfad0-4337-523a-99e2-a2d249319c14","slug":"investigations","fullItemName":"Investigations"}]},{"id":"5da46787-c48f-5e2c-85d7-6a9a17e04771","fullItemName":"Management","slug":"management","subChapters":[{"id":"136349ec-02aa-57d6-97eb-349a8b186b91","slug":"management-of-widespread-itch","fullItemName":"Scenario: Management of widespread itch"}]},{"id":"a5778d5a-8940-58a1-82e1-4801b7a7ea9f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"df24164a-a18e-5781-af2c-9d5424983d04","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"d3b77011-f1f7-5074-ac46-2c0f5e15406a","slug":"hydroxyzine","fullItemName":"Hydroxyzine"}]},{"id":"3bc21e68-6ddb-5e67-9f24-6b13787b7d3c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ebcf77c-c92c-5ef1-9321-590d2e905484","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bff96b70-ee2f-5eed-a1ab-c601465837a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"76e9e0da-5a28-5e8f-a6a8-e08786d8da0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"838c111d-a9e4-5085-b44a-6f220b2e7f9a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8df3d2d7-e38f-5310-8b24-a8509771d9cd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74b7f8a8-8f89-5100-ad47-3f6c473ccaf7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f3e3af3a-d360-5e56-8053-6ff53dac1096","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a5778d5a-8940-58a1-82e1-4801b7a7ea9f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"82183be0-a3c5-5e30-9237-9bce9fb52429","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 20285e67-6753-4118-b9b7-4e1b56c2432f --><h3>Contraindications and cautions</h3><!-- end field 20285e67-6753-4118-b9b7-4e1b56c2432f -->","summary":"","htmlStringContent":"<!-- begin item c64cb8fe-ecd5-483b-953f-68741970ae1c --><!-- begin field 8bf1f6fa-dcd9-4d71-81f3-6ee4c280315b --><ul><li><strong>Hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes,</strong> particularly in people with risk factors for QT prolongation. The Medicines and Healthcare products Regulatory Agency (MHRA) recommends a maximum daily dose of hydroxyzine of 100&nbsp;mg for adults, 50&nbsp;mg for elderly people (if the use of hydroxyzine cannot be avoided), and 2&nbsp;mg per kg bodyweight for children up to 40&nbsp;kg in weight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">MHRA, 2015</a>].</li><li><strong>Do not prescribe hydroxyzine</strong> if the person has:<ul><li>A prolonged QT interval, or risk factors for QT interval prolongation including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">MHRA, 2015</a>]:<ul><li>Use of drugs which prolong the QT interval.</li><li>Cardiovascular disease.</li><li>Family history of sudden cardiac death.</li><li>Low plasma potassium or magnesium levels.</li><li>Significant bradycardia.</li></ul></li><li>Previous history of hypersensitivity to hydroxyzine.</li><li>Asthma with a previous serious antihistamine-induced adverse bronchopulmonary effect.</li></ul></li><li>Hydroxyzine is also contraindicated in pregnancy or breastfeeding.</li><li><strong>Hydroxyzine should be used with caution</strong> in people with:<ul><li>Hepatic impairment &mdash;&nbsp;avoid sedating antihistamines in severe liver disease. In other people with liver impairment, reduce the total daily dose by 33%.</li><li>Renal impairment &mdash; for people with moderate or severe renal impairment, the dose should be reduced by 50%.</li><li>Prostatic hypertrophy.</li><li>Urinary retention.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Severe hypertension.</li><li>Raised intraocular pressure or glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy &mdash; avoid antihistamines if possible, as they may reduce the seizure threshold.</li><li>Asthma, bronchitis, or bronchiectasis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI Medicines Compendium, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">MHRA, 2015</a>]</p><!-- end field 8bf1f6fa-dcd9-4d71-81f3-6ee4c280315b --><!-- end item c64cb8fe-ecd5-483b-953f-68741970ae1c -->","subChapters":[]},{"id":"29ce1189-7c6e-590f-a2b2-8111dc50978e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 033a3705-ba84-48ec-aceb-9d3fb902afcf --><h3>Adverse effects</h3><!-- end field 033a3705-ba84-48ec-aceb-9d3fb902afcf -->","summary":"","htmlStringContent":"<!-- begin item 3cd602a4-42f8-4126-995c-70e965adb7f4 --><!-- begin field 50024a89-50b8-4832-bca2-1c384bdc7f0c --><ul><li>Hydroxyzine has been associated with a small increased risk of QT interval prolongation (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/itch-widespread/prescribing-information/hydroxyzine/#contraindications-cautions\">Hydroxyzine contraindications and cautions</a>).</li><li>Common adverse effects of older antihistamines such as hydroxyzine include:<ul><li>Headache.</li><li>Psychomotor impairment.</li><li>Antimuscarinic effects (for example urinary retention, dry mouth, blurred vision, and gastrointestinal disturbances).</li></ul></li><li>Less common adverse effects include hypotension, palpitations, arrhythmias, dizziness, confusion, tremor, and very rarely Stephens-Johnson syndrome,&nbsp;and erythema multifome.</li><li>Toxic epidermal necrolysis (frequency unknown).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI, 2016</a>]</p><!-- end field 50024a89-50b8-4832-bca2-1c384bdc7f0c --><!-- end item 3cd602a4-42f8-4126-995c-70e965adb7f4 -->","subChapters":[]},{"id":"6faa8f3a-b792-51b2-b35c-0709a837d600","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c05b4153-dc9d-4f31-8332-5d1c010de406 --><h3>Drug interactions</h3><!-- end field c05b4153-dc9d-4f31-8332-5d1c010de406 -->","summary":"","htmlStringContent":"<!-- begin item 7948c7c1-38db-45cb-acc5-26c9a3cce2a7 --><!-- begin field bb991557-fec0-4394-94d3-477606d0ce08 --><ul><li><strong>Avoid prescribing hydroxyzine with:</strong><ul><li>Drugs that prolong the QT interval.</li><li>Monoamine oxidase inhibitors (MAOIs).</li></ul></li><li><strong>Possible drug interactions requiring caution include:</strong><ul><li>Hypnotics and anxiolytics &mdash; may cause an increase in sedative effects.</li><li>Drugs with antimuscarinic properties &mdash; dosage adjustment may be required.</li><li>Cimetidine &mdash; increases the plasma concentration of hydroxyzine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI Medicines Compendium, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>]</p><!-- end field bb991557-fec0-4394-94d3-477606d0ce08 --><!-- end item 7948c7c1-38db-45cb-acc5-26c9a3cce2a7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}